IRD — Opus Genetics Cashflow Statement
0.000.00%
Last trade - 00:00- $38.22m
- $26.74m
- $10.99m
Annual cashflow statement for Opus Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.6 | -56.7 | 17.9 | -9.99 | -57.5 |
| Depreciation | |||||
| Non-Cash Items | 16.7 | 37.1 | 1.98 | 4.79 | 28.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.15 | 0.181 | -5.55 | 4.08 | 3.09 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -6.8 | -19.4 | 14.3 | -1.11 | -25.6 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.539 | -0.1 | 0 | 0 | 1.21 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | 0.539 | -0.1 | 0 | 0 | 1.21 |
| Financing Cash Flow Items | 19.4 | -1.62 | -0.131 | -0.278 | -0.232 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 21.1 | 27.6 | 3.79 | 8.98 | 4.19 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.9 | 8.13 | 18.1 | 7.87 | -20.2 |